CQ Medical

Mentanine® Spray or Syringe method

CBD Patented – Spray or syringe dispensing option Formula

Developed for Anxiety, Depression, PTSD and Addiction

Developed by Dr. Steven Laviolette, Professor and Neuroscientist, and his scientific team at Western University, London, Ontario Canada

New – Disruptive formula – based on science and pre-clinical trials

MENTANINE®:

  • Works synergistically by attaching to a specific endocannabinoid receptor of the metabolic pathway, providing a real “Life Changer” for mental health patients with disorders such as anxiety, depression, and PTSD
  • Reduces inflammation, thus, anticipated to be beneficial for pain management.

Normally, CBD has a low affinity for cannabinoid receptors and only weakly interacts with the CB1 & CB2 receptors, thus achieving nominal results for mental health disorders.

Pre-clinical results

  • Produced anti-anxiety effects.
  • Produced anti-PTSD effects
  • Produced anti-addictive effects; and,
  • Reduction of inflammation, thus, anticipated to be beneficial for pain management.

Bioavailability is extremely critical for effective medical cannabis delivery.

  • The bioavailable formula and the sublingual delivery system provide quicker onset and high absorption (90%) of the active ingredients.
  • 10 times+ the efficacy compared to other CBD products.
  • CBD dosage to be significantly reduced
  • High doses of CBD are costly and create negative side effects.

Accurate dose of pre-packaged volume for precise dosage every time, anywhere

  • No guesswork and precise dose measuring delivery method.
  • Eliminates contamination and oxidation (always closed to the environment).

About Dr. Steven Laviolette:

Professor and Neuroscientist at the Schulich School of Medicine & Dentistry at Western University in London, Ontario. Dr. Laviolette is a leader in the study of cannabinoids in mental health and was recently awarded “Faculty Scholar” status. Dr. Laviolette’s research team has previously made numerous fundamental discoveries related to how cannabinoids impact and may serve as treatments for mental health disorders including schizophrenia, depression, post-traumatic stress disorder and anxiety. Dr. Laviolette’s primary research focus is in characterizing how specific phytochemical derivatives of cannabis may interact with specific brain pathways and molecular mechanisms whereby they may improve symptoms associated with various mental health disorders. Research from Dr. Laviolette’s team has been published in the world’s top tier of neuroscience and psychiatry journals. The following is a link to Dr. Laviolette’s profile on Western University’s website.

http://www.schulich.uwo.ca/anatomy/people/bios/faculty/laviolette_steve.html